Double-blind double-simulate randomized controlled clinical trial on secnidazole tablet in the treatment of trichomonal vaginitis

DONG Xiao-jing,HU Li-na,LIU Hong-wei,ZHOU Ying-fang,ZHANG Shu-lan
DOI: https://doi.org/10.3969/j.issn.1001-6821.2006.02.001
2006-01-01
Abstract:Objective To evaluate the efficacy and safety of secnidazole tablet in the treatment of trichomonal vaginitis. Methods A double-blind double-simulate randomized controlled clinical trail was conducted. Sixty four cases in trial group were given secnidazole tablet and 58 cases in control group were given tinidazole tablet at draught. Vulva pruritus, symptoms of urethritis, leucorrhea, signs as well as pathogens were observed respectively 3~7 day after the end of treatment and 3 to 7 day after menorrhea.Results After treatment, the cure rates were 48.44% in trial group, and 50.00% in control group; the efficacy rates were 93.75 % and 98.28%, the eradicated rates of pathogen were 92.19 % and 98.28 % respectively. Three to 7 days after menorrhea, the cure rates were 57.81% in test group, and 58.62% in control group, the efficacy rates were 92.19 % and 89.66%, the eradicated rates of pathogen were 92.19% and 89.66%, respectively. There was no significant statistic difference between these two groups in efficacy and safety (P>0.05). Conclusion Secnidazole tablet is an effective and safe preparation in the treatment of trichomonal vaginitis.
What problem does this paper attempt to address?